[{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"HT-003","moa":"Toll-like-2 receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aprepitant","moa":"NK-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aprepitant","moa":"NK-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aprepitant","moa":"NK-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aprepitant","moa":"NK-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HT-ALZ","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HT-ALZ","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HT-ALZ","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HT-ALZ","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"HT-ALZ","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"HT-ALZ","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hoth Therapeutics \/ Washington University School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Self-Assembling Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Self-Assembling Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Department of Defense"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"HT-002","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"HT-002","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"George Washington University","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"WEG232","moa":"Substance P receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ George Washington University","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ George Washington University"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WEG232","moa":"Substance P receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Gentamicin Sulfate","moa":"||30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Gentamicin Sulfate","moa":"||30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Private Placement","leadProduct":"Gentamicin Sulfate","moa":"||30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Aprepitant","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aprepitant","moa":"NK-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Aprepitant","moa":"NK-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Washington University School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Reprocell","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"HT-003","moa":"Toll-like-2 receptor","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Reprocell","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Reprocell"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Isoprene Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"HT-003","moa":"Toll-like-2 receptor","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Isoprene Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Isoprene Pharmaceuticals"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Altasciences Company Inc","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"HT-TBI","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Altasciences Company Inc","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Zylo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"HT-005 Z-PODS","moa":"Calcineurin","graph1":"Immunology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ Zylo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Zylo Therapeutics"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Zylo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"HT-005 Z-PODS","moa":"Calcineurin","graph1":"Immunology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ Zylo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Zylo Therapeutics"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Anandamide","moa":"C3 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Anandamide","moa":"C3 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"HT-KIT","moa":"c-KIT receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"HT-KIT","moa":"c-KIT receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"HT-KIT","moa":"c-KIT receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HT-KIT","moa":"c-KIT receptor","graph1":"Hematology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HT-KIT","moa":"c-KIT receptor","graph1":"Hematology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HT-KIT","moa":"c-KIT receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"OnTargetx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"HT-KIT","moa":"c-KIT receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ OnTargetx","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Therapeutics \/ OnTargetx"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"13-cis-RAMBA Retinamide","moa":"MNK1\/2 protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aprepitant","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aprepitant","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aprepitant","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Aprepitant","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Aprepitant","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Charles River Laboratories, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Charles River Laboratories, Inc"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aprepitant","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aprepitant","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aprepitant","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"VNLG 152","moa":"Retinoic acid metabolism","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Retinamide","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Isoprene Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"VNLG 152","moa":"Retinoic acid metabolism","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Isoprene Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Isoprene Pharmaceuticals"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"HT-ALZ","moa":"NK-1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Hoth Therapeutics \/ Washington University School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Aprepitant","moa":"NK-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"HT-ALZ","moa":"NK-1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"HT-KIT","moa":"c-KIT receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Therapeutics \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Hoth Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
